Amgen (NQ: AMGN )
255.71 USD +0.58 (+0.23%) Official Closing Price Updated: 7:45 PM EDT, Apr 16, 2021 Add to My Watchlist
Press releases about Amgen
Two Biotherapeutic Companies Receive Lab Space and Other Benefits to Further Advance Innovative Science at Bay Area Life Sciences Incubator
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
June 19, 2019
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
June 13, 2019
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
June 12, 2019
ADDING MULTIMEDIA Socati Board of Director Appointments Bring Significant Leadership Experience to Accelerate Company Growth, Advance Hemp Industry
June 10, 2019
Socati Board of Director Appointments Bring Significant Leadership Experience to Accelerate Company Growth, Advance Hemp Industry
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday, June 12, 2019, in Rancho Palos Verdes, Calif. David M. Reese, M.D.,...
Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019
June 05, 2019
Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
June 05, 2019
Tags Featured News
Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
June 03, 2019
Amgen (NASDAQ: AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there...
Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
June 02, 2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®
Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
May 29, 2019
Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with...
Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution
May 29, 2019
Amgen Community Oncology Research Collaborators (ACORC) Will Work to Expand Clinical Trial Access to Cancer Patients Treated Outside of Academic Centers
Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at...
Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
May 16, 2019
Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy,...
Amgen Showcases Oncology Pipeline At ASCO 2019
May 15, 2019
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W. Meline, executive vice president and chief financial...
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
May 02, 2019
After Long-Term Aimovig Treatment, Two-Thirds of Chronic Migraine Patients Converted to Episodic Migraine, Experiencing 11 Fewer Migraine Days per Month on Average
Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer
May 01, 2019
Amgen Breakaway Challenge Turns Walking, Running or Cycling Miles Into Support for Eight Independent Nonprofit Advocacy Organizations
Amgen Reports First Quarter 2019 Financial Results
April 30, 2019
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include:
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S. financial markets. The announcement will be followed...
Long-Established Science Education Program to Give Local Secondary School Students Hands-On Biotechnology Lab Experience
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
April 15, 2019